This segment focuses on developing innovative opioid prodrugs designed for effective pain relief while minimizing the potential for abuse and overdose. Ensysce's proprietary Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms are central to this effort. Research and development activities include preclinical studies, clinical trials, and formulation optimization to enhance drug delivery and abuse deterrence. The therapeutic area is severe pain management, addressing the needs of patients requiring strong analgesics. The patient impact is significant, aiming to provide safer and more effective pain relief options. Market positioning involves competing with traditional opioid formulations by offering superior abuse-deterrent properties. Future opportunities include expanding the product pipeline and securing regulatory approvals for new drug candidates. Regulatory and clinical aspects involve rigorous testing and adherence to FDA guidelines to ensure safety and efficacy. Partnerships and collaborations are essential for scaling manufacturing and commercializing these novel pain management solutions.